Hims & Hers Health Inc. (简称Hims & Hers) 股价延续上涨态势，此前该公司与丹麦制药巨头诺和诺德(Novo Nordisk)达成合作协议，获得销售减肥药Wegovy和糖尿病药物Ozempic的授权。与此同时，诺和诺德已同意撤销对Hims & Hers提起的相关法律诉讼。
这一合作标志着Hims & Hers正式进军GLP-1受体激动剂类药物的零售市场，有望显著拓展其远程医疗平台的产品矩阵。受此消息提振，Hims & Hers股价在盘前交易中继续攀升，延续了近期因市场对减肥药物业务布局预期而引发的上涨行情。
分析人士指出，此次合作不仅解决了双方的法律纠纷，更为Hims & Hers打开了高达千亿美元的减肥药物市场大门。随着诺和诺德旗下明星产品Wegovy和Ozempic的加入，Hims & Hers的健康服务生态系统将得到进一步完善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.